Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Krystal Biotech

Request full access

Makes a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases

Pittsburgh, United StatesFounded 2016Biotech & Life Sciences
Valuation $9.06B Market cap · 2026
Revenue $516M Latest reported FY
EBITDA $261M Latest reported FY

About Krystal Biotech

Krystal Biotech is a biotechnology company focused on the development and commercialization of gene therapies for patients with rare diseases. The company's lead product candidate is VYJUVEK® (beremagene geperpavec-svdt), a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disease. VYJUVEK is the first-ever redosable gene therapy and the first and only medicine approved by the FDA for the treatment of DEB, for which the company holds exclusive worldwide rights.

Krystal Biotech's business model revolves around its proprietary STAR-D gene therapy platform, which enables the development of off-the-shelf treatments for a wide range of dermatological diseases. The company's revenue is primarily generated from the sale of VYJUVEK. Krystal Biotech serves a niche market of patients with rare dermatological conditions, working closely with healthcare professionals and patient advocacy groups to provide access to its treatments. The company is publicly traded on the Nasdaq stock exchange under the ticker symbol KRYS.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2016
Headquarters
Pittsburgh, United States
Listing
IPO 2017
Sector
Biotech & Life Sciences
Outcome tier
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Krystal Biotech in the Pittsburgh ecosystem

Live from Dealroom

The Krystal Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Sun Pharmaceutical Industries

Series B and later2 investors entered at this stage

  • Redmile Group
  • Avoro Capital Advisors
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States89.1%
🇩🇪 Germany3.4%
🇨🇭 Switzerland3.4%
🇫🇷 France2.5%
🇯🇵 Japan1.3%
Top 5 of 6 shown
Web traffic by country
12K monthly visits
across markets
🇺🇸 United States59.2%
🇨🇦 Canada15.8%
🇬🇧 United Kingdom11.7%
🇮🇳 India10%
🇯🇵 Japan1.7%
Top 5 markets shown

Patents

Estimated portfolio value
$21M

19 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Krystal Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Krystal Biotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.